Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARñ and PPARó, proposed for the management of type 2 diabetes.
The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca announced that it had discontinued further development.
Cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in PPARó coactivator 1-ñ (PPARGC1A, PGC1ñ) and sirtuin 1 (SIRT1).